These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25270749)

  • 41. [Planning sample size in ophthalmologic studies].
    Krummenauer F; Dick B; Schwenn O; Pfeiffer N
    Klin Monbl Augenheilkd; 2000 Jan; 216(1):2-9. PubMed ID: 10702936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimating sample size in clinical studies: basic methodological principles.
    Carneiro AV
    Rev Port Cardiol; 2003 Dec; 22(12):1513-21. PubMed ID: 15008067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.
    Whitehead J; Cleary F; Turner A
    Stat Med; 2015 May; 34(12):2048-61. PubMed ID: 25765252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sample size calculation for an agreement study.
    Liao JJ
    Pharm Stat; 2010; 9(2):125-32. PubMed ID: 19507134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sample size calculations in clinical research should also be based on ethical principles.
    Cesana BM; Antonelli P
    Trials; 2016 Mar; 17(1):149. PubMed ID: 26993625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On the lower predictive bound approach for noninferiority clinical trials with binary data.
    Liu Q; Li Y
    J Biopharm Stat; 2014; 24(6):1225-38. PubMed ID: 25036815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calculation of tolerance limits and sample size determination for clinical trials with dichotomous outcomes.
    Zaslavsky BG
    J Biopharm Stat; 2007; 17(3):481-91. PubMed ID: 17479395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sample size determination in step-up testing procedures for multiple comparisons with a control.
    Kwong KS; Cheung SH; Wen MJ
    Stat Med; 2010 Nov; 29(26):2743-56. PubMed ID: 20799258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ambulatory blood pressure monitoring in the design of antihypertensive drug trials.
    Conway J; Coats AJ
    J Hypertens Suppl; 1991 Dec; 9(8):S57-8. PubMed ID: 1795203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design principles and statistical considerations in periodontal clinical trials.
    Koch GG; Paquette DW
    Ann Periodontol; 1997 Mar; 2(1):42-63. PubMed ID: 9151542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival endpoints and adaptive designs.
    Bauer P
    Biom J; 2006 Aug; 48(4):730-1. PubMed ID: 16972725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The most frequently asked question to a statistician: The sample size.
    Sormani MP
    Mult Scler; 2017 Apr; 23(5):644-646. PubMed ID: 28273773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statistical inference for clinical trials with binary responses when there is a shift in patient population.
    Yang LY; Chi Y; Chow SC
    J Biopharm Stat; 2011 May; 21(3):437-52. PubMed ID: 21442518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Corrected profile likelihood confidence interval for binomial paired incomplete data.
    Pradhan V; Menon S; Das U
    Pharm Stat; 2013; 12(1):48-58. PubMed ID: 23296487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. On power and sample size calculation for QT studies with recording replicates at given time point.
    Chow SC; Cheng B; Cosmatos D
    J Biopharm Stat; 2008; 18(3):483-93. PubMed ID: 18470757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting where future means will lie based on the results of the current trial.
    Julious SA; Campbell MJ; Walters SJ
    Contemp Clin Trials; 2007 Jul; 28(4):352-7. PubMed ID: 17368114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.